Administrative Core Abstract The purpose of the administrative core is to organize the components of the DF/HCC Spore in Myeloid Malignancies and to provide oversight and leadership of the scientific, administrative, and fiscal aspects of this SPORE. The SPORE Directors, Dr. Benjamin Ebert and Dr. Richard Stone, will oversee the administrative coordination of the various clinical and laboratory studies outlined in this program. They will integrate efforts within and between projects and cores thereby promoting rapid movements of findings to benefit patients as well as the initiation of laboratory studies stemming from clinical observations. This SPORE infrastructure will facilitate critical communication and exchange of data between SPORE leukemia sites to facilitate collaborative pre-clinical studies and clinical trials. The administrative core functions will include organization of meetings and direction from the external advisory board, internal advisory board, and governance committee. The governance committee will be responsible for solicitation, review, and oversight of career development and developmental research projects. The administrative core will monitor the progress of the entire SPORE. This will include oversight of the projects and cores. The SPORE director will be responsible, in conjunction with the governance committee for promotion of developmental projects into translational projects and/or terminate a translational project if required. The Core will facilitate the interchange of research information between SPOREs within the DF/HCC, guide collaboration and retreats with other leukemia SPOREs, and disseminate information about the Clinical Development Awards and Developmental Research Projects within the SPORE itself.
The Specific Aims of the Administration Core are: 1) to monitor research projects and Cores and plan for the future; 2) to foster collaborative research within the SPORE and between SPOREs; 3) to integrate the SPORE in Myeloid Leukemias into the DF/HCC structure; 4) to provide necessary resources for fiscal oversight; and 5) to promote rapid dissemination of significant research findings.

Public Health Relevance

Administrative Core Project Narrative To guide the research described in the SPORE, to assess progress, and to develop the careers of new investigators, an effective and active organizational structure is required. The efforts proposed in the Core will enable effective SPORE management to aid in the development of novel therapeutic strategies in myeloid malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA206963-02
Application #
9567520
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
Pikman, Yana; Stegmaier, Kimberly (2018) Targeted therapy for fusion-driven high-risk acute leukemia. Blood 132:1241-1247
DeAngelo, Daniel J; Brunner, Andrew M; Werner, Lillian et al. (2018) A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol 93:254-261
Nakamura, Makoto; Wu, Lizi; Griffin, James D et al. (2018) Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors. Leuk Res 72:34-44
Sievers, Quinlan L; Petzold, Georg; Bunker, Richard D et al. (2018) Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362:
Fink, Emma C; McConkey, Marie; Adams, Dylan N et al. (2018) CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132:1535-1544
Gibson, Christopher J; Kennedy, James A; Nikiforow, Sarah et al. (2017) Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood 130:91-94
Ho, Vincent T; Kim, Haesook T; Bavli, Natalie et al. (2017) Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv 1:2269-2279
Ajore, Ram; Raiser, David; McConkey, Marie et al. (2017) Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. EMBO Mol Med 9:498-507
Gibson, Christopher J; Lindsley, R Coleman; Tchekmedyian, Vatche et al. (2017) Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol 35:1598-1605
Weisberg, Ellen L; Puissant, Alexandre; Stone, Richard et al. (2017) Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget 8:52026-52044

Showing the most recent 10 out of 13 publications